A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)

Homozygous Familial Hypercholesterolemia Clinical Trial

Official title:

A Phase III Study of Microsomal Triglyceride Transfer Protein (MTP) Inhibitor AEGR-733 in Patients With Homozygous Familial Hypercholesterolemia on Current Lipid-lowering Therapy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00730236
• Other study ID #: AEGR-733-005 / UP1002
• Status: Completed
• Phase: Phase 3
• First received: August 6, 2008
• Last updated: February 21, 2018
• Start date: December 2007
• Est. completion date: October 2011

Study information

• Verified date: January 2013
• Source: Aegerion Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this trial is to study the effects of AEGR-733 on LDL cholesterol, other lipids as well as measures of safety over the long-term.

Description:

Homozygous familial hypercholesterolemia (FH) is a serious life-threatening genetic disease. Total plasma cholesterol levels are generally over 500 mg/dl and markedly premature cardiovascular disease is the major consequence. Untreated, most patients develop atherosclerosis before age 20 and generally do not survive past age 30. The primary goal of therapy involves reducing cholesterol (specifically, LDL cholesterol) and preventing coronary artery disease. Unfortunately, patients with homozygous FH are minimally responsive or unresponsive to available drug therapy and thus there are limited treatment options. The current standard of care is LDL apheresis, a physical method of removing the plasma of LDL cholesterol which can transiently reduce cholesterol by more than 50%. However, there is rapid re-accumulation of LDL cholesterol in plasma, and therefore apheresis has to be repeated frequently (every 1-2 weeks) and requires 2 separate sites for IV access. Although anecdotally this procedure may delay the onset of atherosclerosis, it is laborious, expensive, and not readily available. Furthermore, although it is a procedure that is generally well tolerated, the fact that it needs frequent repetition and IV access can be challenging for many of these young patients. Therefore, there is a tremendous unmet medical need for new medical therapies for this orphan disease.

AEGR-733 is a novel oral therapeutic agent for hypercholesterolemia. Its mechanism involves inhibition of microsomal triglyceride transfer protein, resulting in a reduction of LDL cholesterol. Earlier studies in patients with homozygous FH reveal AEGR-733 is highly effective in lowering LDL cholesterol, yet long term safety and efficacy need to be established.

Other known NCT identifiers

• NCT00603161

Recruitment information / eligibility

• Status: Completed
• Enrollment: 29
• Est. completion date: October 2011
• Est. primary completion date: September 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Males and females at least 18 years of age

2. Diagnosis of functional homozygous FH by at least one (a-c) of the following clinical criteria:

• documented functional mutation(s) in both LDL receptor alleles or alleles known to affect LDL receptor functionality OR

• skin fibroblast LDL receptor activity less than 20% normal OR

• untreated TC greater than 500 mg/dL AND TG less then 300 mg/dL AND both parents have documented TC greater than 250 mg/dL

3. Concurrent lipid lowering medication/apheresis must be stable for at least 6 weeks before the baseline visit and must remain stable for the first 26 weeks.

4. Body weight at least 40 kg and less than 136 kg

5. Negative screening pregnancy test if female of child-bearing potential (females of child-bearing potential and all males must be following a medically accepted form of contraception)

6. Subjects must be willing to comply with all study-related procedures

Exclusion Criteria:

1. Uncontrolled hypertension

2. History of chronic renal insufficiency

3. History of biopsy proven cirrhosis or abnormal LFTs at screening (AST or ALT greater than 2 x upper limit of normal and/or Total Bilirubin greater than or equal to 1.5 mg/dl unless patient has unconjugated hyperbilirubinemia due to Gilbert's syndrome)

4. Chronic hepatitis B or chronic hepatitis C

5. Any major surgical procedure occurring less than 3 months prior to the screening visit

6. Cardiac insufficiency defined by the NYHA classification as functional Class III or Class IV

7. Previous organ transplantation

8. History of a non-skin malignancy within the previous 3 years

9. Male subjects reporting more than 2 drinks per day or females reporting more than 1 drink per day (1 drink= 12 oz beer, 1 oz hard liquor, 5 oz wine).

10. Participation in an investigational drug study within 6 weeks prior to the screening visit

11. Known significant gastrointestinal bowel disease or malabsorption such as inflammatory bowel disease or chronic pancreatitis requiring use of daily pancreatic enzymes.

12. Serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study.

13. Certain prohibited medications known to be potentially hepatotoxic, especially those that can induce microvesicular or macrovesicular steatosis. These include but are not limited to: accutane, amiodarone, heavy acetaminophen use (4g/day greater than 3 x q week), methotrexate, tetracyclines,and tamoxifen

14. Documented diagnosis of any of the following pulmonary conditions: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Idiopathic pulmonary fibrosis

15. Documented diagnosis of any of the following liver diseases: Nonalcoholic Steatohepatitis, Alcoholic liver disease, Autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, Wilson's disease, hemochromatosis, alpha 1 anti-trypsin deficiency.

16. Current use of corticosteroids or betaine

Related Conditions & MeSH terms

• Homozygous Familial Hypercholesterolemia
• Hypercholesterolemia
• Hyperlipoproteinemia Type II

Intervention

Drug:
• AEGR-733
5-80 mg daily by mouth for 1.5 yrs

Locations

Country	Name	City	State
Canada	Lipid Clinic and University of Montreal Community Genomic Medicine Center	Chicoutimi	Quebec
Canada	Robarts Research Institute	London	Ontario
Italy	Medicina Interna Universitaria	Ferrara
Italy	Centro Universitario Dislipidemie	Milano
Italy	Dipartimento di Medicina Clinica e Della Patalogie Emergenti	Palermo	Sicily
Italy	Dipartimento di Clinica e Terapia Medica	Roma
South Africa	Cardiology Research	Bloemfontein
South Africa	University of Capetown	Cape town
United States	Cedars-Sinai Medical Center	Los Angeles	California
United States	University of Pennsylvania	Philadelphia	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
Aegerion Pharmaceuticals, Inc.	FDA Office of Orphan Products Development

Countries where clinical trial is conducted

United States,  Canada,  Italy,  South Africa, 

References & Publications (2)

Cuchel M, Bloedon LT, Szapary PO, Kolansky DM, Wolfe ML, Sarkis A, Millar JS, Ikewaki K, Siegelman ES, Gregg RE, Rader DJ. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007 Jan 11;356(2):148-56. — View Citation

Cuchel M, Meagher E, Marais AD, et.al. Abstract 1077: A phase III study of microsomal triglyceride transfer protein inhibitor lomitapide (AEGR-733) in patients with homozygous familial hypercholesterolemia: interim results at 6 months. Circulation, Nov 20

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)	Percent change from Baseline in LDL-C	Baseline and Week 26
Secondary	Percent Change From Baseline in Total Cholesterol (TC)	Percent change from Baseline in TC	Baseline and Week 26
Secondary	Percent Change From Baseline for Apolipoprotein B (Apo B)	Percent change from Baseline for Apo B	Baseline and Week 26
Secondary	Percent Change From Baseline in Triglycerides	Percent change from Baseline in triglycerides	Baseline and Week 26
Secondary	Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C)	Percent change from Baseline in HDL-C	Baseline and Week 26
Secondary	Percent Change From Baseline in Non-HDL-C	Percent change from Baseline in non-HDL-C	Baseline and Week 26
Secondary	Percent Change From Baseline in Apolipoprotein AI (Apo AI)	Percent change from Baseline in Apo AI	Baseline and Week 26
Secondary	Absolute Change From Baseline in Hepatic Fat Percent	Absolute change from Baseline in hepatic fat percent	Baseline and Week 78
Secondary	Absolute Change From Baseline in Alanine Aminotransferase (ALT)	Absolute change from Baseline in ALT	Baseline and Week 78
Secondary	Absolute Change From Baseline in Aspartate Aminotransferase (AST)	Absolute change from Baseline in AST	Baseline and Week 78
Secondary	Absolute Change From Baseline in Total Bilirubin	Absolute change from Baseline in total bilirubin	Baseline and Week 78
Secondary	Absolute Change From Baseline in Weight	Absolute change from Baseline in weight	Baseline and Week 78